Just another WordPress site
Investment Type: Venture Capital
Portfolio 5
| Date | Name | Website | Total Raised | Location |
| - | Reaction B... | reactionbiology.com | - | United Sta... |
| - | Knopp Bios... | knoppbio.com | $19M | United Sta... |
| - | Celsense | celsense.com | - | - |
| - | Crystalple... | crystalplex.com | - | - |
| - | Immunetric... | immunetrics.com | - | United Sta... |
Mentions in press and media 11
| Date | Title | Description |
| 14.11.2012 | Drug developer advancing Phase 2 drug for Lou Gehrig’s disease raises $15M | Product: Its lead product is dexpramipexole for amyotrophic lateral sclerosis or Lou Gehrig’s disease and is being developed with Biogen. It is designed to protect stressed neurons and other cell types from dying, according to its website. ... |
| 13.07.2012 | Biotechnology firm raising $30M to advance treatment for Parkinson’s, neurodegenerative disease | Since it forged a licensing deal with Biogen in 2010 for its ALS drug dexpramipexole, Knopp has doubled its research and development facilities and increased its staff to 33. In May, it hired Dr. Steven Boyd, formerly of Array BioPharma and... |
| 06.06.2011 | LaunchCyte raises $1.1M to commercialize biotech discoveries | The latest funding, $1.055 million, comes in the form of equity and is anticipated to be part of a $1.575 million fundraise. It was sourced from six investors, according to the regulatory document. LaunchCyte’s portfolio companies include I... |
| 22.06.2010 | LaunchCyte raises $1 million | By Brandon Glenn Biotechnology commercialization company LaunchCyte LLC raised nearly $1 million in debt, options and warrants, according to a filing with the Securities & Exchange Commission. The company pulled in $927,000 of the nearl... |
| 21.06.2010 | Biotech commercialization firm LaunchCyte raises nearly $1M | It’s unclear what plans LaunchCyte has for its latest round of funding. CEO Tom Petzinger didn’t return a call. LaunchCyte’s portfolio companies include Immunetrics Inc., which develops software for clinical trials, Celsense Inc., which off... |
| 25.09.2009 | Pittsburgh’s Knopp NeuroSciences raising $12.5 million for ALS drug | Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| - | LaunchCyte raises $1.1M to commercialize biotech discoveries | Biotechnology commercialization company LaunchCyte has raised nearly $1.1 million in equity, according to a regulatory filing. The Pittsburgh-based company’s business model is similar to that of an incubator in that it helps start and grow ... |
| - | Drug developer advancing Phase 2 drug for Lou Gehrig’s disease raises $15M | Company name: Knopp Biosciences Industry: Biotechnology Location: Pittsburgh, Pennsylvania Product: Its lead product is dexpramipexole for amyotrophic lateral sclerosis or Lou Gehrig’s disease and is being developed with Biogen. It is desig... |
| - | Biotech commercialization firm LaunchCyte raises nearly $1M | Biotechnology commercialization company LaunchCyte LLC has raised just less than $1 million in debt, options and warrants, according to a filing with the Securities and Exchange Commission. The company has pulled in $927,000 of an anticipat... |
| - | Pittsburgh’s Knopp NeuroSciences raising $12.5 million for ALS drug | PITTSBURGH, Pennsylvania — Knopp NeuroSciences, which is rapidly developing a drug to treat Lou Gehrig’s disease, is raising $12.5 million, according to a filing with the Securities and Exchange Commission. The company’s drug earlier this m... |
Show more